TXMD TherapeuticsMD, Inc. Insider Trading

Director Thompson buys 8,400 shares of TXMD at $1.67; holdings surge 56.8%; prior TXMD buy achieved 17.8% 90d gain.

Director Tommy G Thompson purchased 8,400 shares of TherapeuticsMD at $1.67, increasing his holdings by 56.8% to 23,179 shares. His prior purchase of TXMD stock on 2025-04-14 delivered a 17.8% 90-day return, establishing a pattern of well-timed accumulation at this ticker. The stock currently trades at $1.68, near the transaction price, within its 52-week range and 56.3% above its 90-day low. The company posted $784,000 quarterly revenue and $152,000 net income, though the full fiscal year was unprofitable. The acquisition follows recent positive price momentum while the company remains early-stage, with a P/E of 56.00 and a $19.4M market cap.

Director Tommy G Thompson buys 325 TXMD shares at $1.00; holder of 14.8K shares, stock down 53.2% from 52-week high.

Director Thompson G purchased 325 shares of TherapeuticsMD at $1.00, increasing his holdings to 14,779 shares. The company is unprofitable, posting quarterly revenue of $-53.0K and net income of $-1.1M in the latest period, though full-year revenue growth of 35.2% shows operating expansion. The stock trades at $1.04 currently, having fallen 53.2% from its 52-week high of $2.22 while rebounding 43.4% over the past 30 days. This modest share purchase—worth $325.59—represents a small addition to existing holdings (2.2% increase) and lacks the scale or context to indicate a conviction-driven accumulation stance.

TXMD CEO Walker Marlan D bought 490 shares at $1.00 on 2025-04-14, third consecutive purchase in five days amid unprofitable operations.

CEO Walker Marlan D purchased 490 shares at $1.00 on 2025-04-14, marking his third consecutive buy within a five-day span (following purchases on 2025-04-09 and 2025-04-10). The accumulated purchases total 550 shares across three days, suggesting sustained accumulation despite market headwinds. TherapeuticsMD reported revenue of $-53,000.00 and net income of $-1,090,000.00 in the latest quarter, with the company unprofitable over its most recent full fiscal year. While annual revenue growth shows +35.2%, the stock trades at -53.2% from its 52-week high of $2.22, and the CEO's immediate $1.00 entry point is just 3.8% below the current $1.04 price, suggesting minimal price movement post-purchase. The rapid succession of buys without prior cross-ticker execution pattern (only 2 prior buys across all tickers in the insider's history) warrants examination of whether these reflect opportunistic accumulation or scheduled activity not disclosed in the filing.

CEO Walker Marlan D purchases 2,303 shares at blended $0.87, increasing holdings 3.3% to 73,149 shares at struggling biotech.

Walker Marlan D, Chief Executive Officer of TherapeuticsMD (TXMD), made 2 separate purchases on April 9-10, 2025, acquiring 2,303 shares totaling $1,994.01 at a blended average price of $0.87. The purchases occur in a company with significant operational headwinds: latest quarterly revenue was $-53,000.00, net income stands at $-1,090,000.00, and the company posted negative full-year net income. The stock trades at $0.88 currently, down 60.4% from its 52-week high of $2.22, though it has gained 15.6% over the past 30 days and fallen 20.0% over 90 days. The CEO's holdings grew from 70,846 to 73,149 shares (+3.3%), reflecting a modest increase in personal exposure. This insider purchase occurs in a micro-cap ($10.2M) biotech with fundamental losses, where the transaction price matches the current market price, and should be evaluated in light of the company's negative revenue run rate and persistent unprofitability.

Director Collins Cooper C. bought 4,094 shares of TXMD at $1.73 on 2024-08-22; stock now -53.1% from 52-week high amid -98.1% annual revenue decline.

Collins Cooper C. purchased 4,094 shares at $1.73, bringing his holdings to 52,016 shares (+8.5%). This marks his second consecutive day of buying at TherapeuticsMD (a prior buy occurred on 2024-08-21), albeit in a company facing severe headwinds: annual revenue contracted by -98.1%, the latest quarter reported negative $53,000.00 in revenue, and net income was negative $1,090,000.00. The stock trades at -53.1% from its 52-week high of $4.03. Without scheduled trading plan disclosure in this filing, the rapid back-to-back purchases at distressed valuations occur against a backdrop of fundamental deterioration, leaving the trade's motivation opaque to investors.

Director Collins Cooper C. buys 1,200 shares of TXMD at $1.70; stock down -56.1% from 52-week high amid -98.1% revenue decline.

Collins Cooper C., a Director, purchased 1,200 shares at $1.70 on 2024-08-21, increasing his holdings from 46,722 to 47,922 shares. The purchase occurs against a deteriorating fundamental backdrop: the company posted negative revenue of -$53,000.00 in the latest quarter, annual revenue growth of -98.1%, and a full-year net income of -$1,090,000.00. The stock trades at $1.77 currently, down -56.1% from its 52-week high of $4.03 and -17.3% over 90 days. This represents the director's second transaction at TXMD (a prior buy on 2024-08-22, outcome not yet measurable) with limited cross-ticker purchase history (1 prior buy across all tickers). The modest share acquisition in the context of severe revenue collapse and unprofitable operations provides limited clarity on insider conviction given the company's acute financial distress.